CDER’s Sequestration Strategy Aided By 400 Missing FTEs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s ability to avoid furloughs under sequester is not good news, OND Director John Jenkins says, but instead is a sign of severe understaffing that already existed.
You may also be interested in...
ANDA Pre-Submission Meetings Being Considered By FDA
Designed to boost application quality, creating such meetings would be another sign of the evolution of the Office of Generic Drugs.
PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin
Twenty sponsors now have applications in the new review model, but none have reached the approval decision stage; industry officials say it still is too early to draw conclusions.
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.